Vertex Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Vertex Pharmaceuticalsの CEO はReshma Kewalramaniで、 Apr2020年に任命され、 の在任期間は 4.58年です。 の年間総報酬は$ 20.59Mで、 7.3%給与と92.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.029%を直接所有しており、その価値は$ 33.94M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と4.8年です。
主要情報
Reshma Kewalramani
最高経営責任者
US$20.6m
報酬総額
| CEO給与比率 | 7.3% |
| CEO在任期間 | 4.6yrs |
| CEOの所有権 | 0.03% |
| 経営陣の平均在職期間 | 5.1yrs |
| 取締役会の平均在任期間 | 4.8yrs |
経営陣の近況
Recent updates
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$480m |
| Jun 30 2024 | n/a | n/a | -US$490m |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$16m | US$1m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$9m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$702k | US$1b |
報酬と市場: Reshmaの 総報酬 ($USD 20.59M ) は、 US市場 ($USD 12.73M ) の同規模の企業の平均を上回っています。
報酬と収益: Reshmaの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Reshma Kewalramani (51 yo)
4.6yrs
在職期間
US$20,594,441
報酬
Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 15.3yrs | US$6.60m | 0.0040% $ 4.7m | |
| CEO, President & Director | 4.6yrs | US$20.59m | 0.029% $ 33.9m | |
| Executive VP & CFO | 5.6yrs | US$7.37m | 0.017% $ 19.8m | |
| Executive VP & COO | 3.3yrs | US$9.00m | 0.019% $ 22.3m | |
| Executive VP & Chief Scientific Officer | 9.8yrs | US$6.54m | 0.010% $ 11.6m | |
| Senior VP & Chief Accounting Officer | 3.5yrs | データなし | 0.0029% $ 3.4m | |
| SVP and Chief Information & Data Officer | 5.8yrs | データなし | データなし | |
| Senior Vice President of Investor Relations | 2.2yrs | データなし | データなし | |
| Executive VP & Chief Legal Officer | 2.2yrs | データなし | 0.0065% $ 7.5m | |
| Senior VP & Chief Communications Officer | 5.8yrs | データなし | データなし | |
| Senior VP & Chief Human Resources Officer | 7.3yrs | データなし | データなし | |
| Executive VP & Chief Patient and External Affairs Officer | 17.3yrs | US$6.20m | 0.023% $ 26.1m |
5.1yrs
平均在職期間
57yo
平均年齢
経験豊富な経営陣: VRTXの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 15.3yrs | US$6.60m | 0.0040% $ 4.7m | |
| CEO, President & Director | 4.8yrs | US$20.59m | 0.029% $ 33.9m | |
| Lead Independent Director | 26.8yrs | US$600.04k | 0.016% $ 17.9m | |
| Independent Director | 7.4yrs | US$537.63k | 0.0023% $ 2.6m | |
| Independent Director | 5.8yrs | US$559.79k | 0.0021% $ 2.4m | |
| Independent Director | 9.4yrs | US$550.31k | 0.0013% $ 1.5m | |
| Independent Director | 1.1yrs | US$449.08k | データなし | |
| Independent Director | 4.4yrs | US$553.11k | 0.00064% $ 738.4k | |
| Independent Director | 2.5yrs | US$544.66k | 0.00060% $ 692.3k | |
| Independent Director | less than a year | US$407.65k | データなし | |
| Independent Director | less than a year | データなし | データなし |
4.8yrs
平均在職期間
59yo
平均年齢
経験豊富なボード: VRTXの 取締役会 は 経験豊富 であると考えられます ( 4.8年の平均在任期間)。